2.7.11.20	Acidosis	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12416990&form=6&db=m	Regulation of elongation factor-2 kinase by pH.	causal interaction,therapeutic application,unassigned	4,3,0	
2.7.11.20	Acidosis	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25670349&form=6&db=m	Regulated stability of eukaryotic elongation factor 2 kinase requires intrinsic but not ongoing activity.	ongoing research,therapeutic application,unassigned	3,4,0	
2.7.11.20	Acidosis	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25776553&form=6&db=m	Molecular Mechanism for the Control of Eukaryotic Elongation Factor 2 Kinase by pH: Role in Cancer Cell Survival.	causal interaction,diagnostic usage,ongoing research,therapeutic application	3,4,4,2	
2.7.11.20	Acidosis	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33673713&form=6&db=m	Progress in the Development of Eukaryotic Elongation Factor 2 Kinase (eEF2K) Natural Product and Synthetic Small Molecule Inhibitors for Cancer Chemotherapy.	causal interaction,therapeutic application,unassigned	4,4,0	
2.7.11.20	Acquired Immunodeficiency Syndrome	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29186827&form=6&db=m	Eukaryotic Elongation Factor 2 Kinase (eEF2K) in Cancer.	causal interaction,diagnostic usage,therapeutic application,unassigned	4,3,4,0	
2.7.11.20	Adenocarcinoma	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34352439&form=6&db=m	eEF2K as a novel metastatic and prognostic biomarker in gastric cancer patients.	causal interaction,diagnostic usage,ongoing research,therapeutic application	2,4,4,3	
2.7.11.20	Adenocarcinoma of Lung	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30890561&form=6&db=m	Ablation of elongation factor 2 kinase enhances heat-shock protein 90 chaperone expression and protects cells under proteotoxic stress.	causal interaction,ongoing research,therapeutic application,unassigned	1,4,1,0	
2.7.11.20	Alzheimer Disease	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16098202&form=6&db=m	Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain.	causal interaction,unassigned	3,0	
2.7.11.20	Alzheimer Disease	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30667373&form=6&db=m	Genetic reduction of eEF2 kinase alleviates pathophysiology in Alzheimer's disease model mice.	causal interaction,ongoing research,therapeutic application,unassigned	4,2,1,0	
2.7.11.20	Anemia	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17110456&form=6&db=m	Regulation of protein synthesis by the heme-regulated eIF2alpha kinase: relevance to anemias.	causal interaction,unassigned	1,0	
2.7.11.20	Anemia	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17932563&form=6&db=m	The function of heme-regulated eIF2alpha kinase in murine iron homeostasis and macrophage maturation.	unassigned	-	
2.7.11.20	Atherosclerosis	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25475470&form=6&db=m	Impairing eukaryotic elongation factor 2 kinase activity decreases atherosclerotic plaque formation.	causal interaction,ongoing research,therapeutic application,unassigned	4,4,4,0	
2.7.11.20	Atherosclerosis	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32088293&form=6&db=m	Eukaryotic Elongation Factor 2 Kinase a Pharmacological Target to Regulate Protein Translation Dysfunction in Neurological Diseases.	causal interaction,therapeutic application,unassigned	4,4,0	
2.7.11.20	beta-Thalassemia	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15931390&form=6&db=m	Heme-regulated eIF2alpha kinase modifies the phenotypic severity of murine models of erythropoietic protoporphyria and beta-thalassemia.	causal interaction,unassigned	2,0	
2.7.11.20	beta-Thalassemia	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17932563&form=6&db=m	The function of heme-regulated eIF2alpha kinase in murine iron homeostasis and macrophage maturation.	unassigned	-	
2.7.11.20	beta-Thalassemia	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18367482&form=6&db=m	Deficiency of heme-regulated eIF2alpha kinase decreases hepcidin expression and splenic iron in HFE-/- mice.	causal interaction,ongoing research,unassigned	4,4,0	
2.7.11.20	Brain Ischemia	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10072297&form=6&db=m	Eukaryotic initiation factor 2alpha kinase and phosphatase activity during postischemic brain reperfusion.	ongoing research,therapeutic application,unassigned	2,1,0	
2.7.11.20	Brain Ischemia	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15006693&form=6&db=m	Oxidative injury to the endoplasmic reticulum in mouse brains after transient focal ischemia.	ongoing research,therapeutic application,unassigned	2,1,0	
2.7.11.20	Brain Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32027127&form=6&db=m	Design, Synthesis, and Molecular Modeling Studies of Novel Coumarin Carboxamide Derivatives as eEF-2K Inhibitors.	causal interaction,diagnostic usage,ongoing research,therapeutic application	4,3,4,1	
2.7.11.20	Breast Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10408694&form=6&db=m	Activity and regulation by growth factors of calmodulin-dependent protein kinase III (elongation factor 2-kinase) in human breast cancer.	causal interaction,diagnostic usage,ongoing research,therapeutic application	4,4,4,1	
2.7.11.20	Breast Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16648488&form=6&db=m	Hypoxia inhibits protein synthesis through a 4E-BP1 and elongation factor 2 kinase pathway controlled by mTOR and uncoupled in breast cancer cells.	ongoing research,therapeutic application,unassigned	3,1,0	
2.7.11.20	Breast Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20300520&form=6&db=m	Cytoprotective effect of the elongation factor-2 kinase-mediated autophagy in breast cancer cells subjected to growth factor inhibition.	causal interaction,ongoing research,unassigned	4,2,0	
2.7.11.20	Breast Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22352903&form=6&db=m	Investigating the Kinetic Mechanism of Inhibition of Elongation Factor 2 Kinase by NH125: Evidence of a Common in Vitro Artifact.	ongoing research,therapeutic application,unassigned	1,1,0	
2.7.11.20	Breast Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22911754&form=6&db=m	Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to Doxorubicin in an orthotopic model of breast cancer.	causal interaction,ongoing research,therapeutic application,unassigned	4,3,4,0	
2.7.11.20	Breast Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23102376&form=6&db=m	Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer.	causal interaction,diagnostic usage,therapeutic application,unassigned	4,3,1,0	
2.7.11.20	Breast Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24078616&form=6&db=m	High-Throughput Screens for eEF-2 Kinase.	causal interaction,therapeutic application,unassigned	4,4,0	
2.7.11.20	Breast Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25047940&form=6&db=m	Synthesis and biological evaluation of pyrido[2,3-d]pyrimidine-2,4-dione derivatives as eEF-2K inhibitors.	unassigned	-	
2.7.11.20	Breast Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26776155&form=6&db=m	Integrative bioinformatics and proteomics-based discovery of an eEF2K inhibitor (cefatrizine) with ER stress modulation in breast cancer cells.	causal interaction,ongoing research,therapeutic application,unassigned	4,2,4,0	
2.7.11.20	Breast Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26918606&form=6&db=m	FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.	causal interaction,diagnostic usage,ongoing research,therapeutic application	4,2,4,1	
2.7.11.20	Breast Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29202403&form=6&db=m	Design, synthesis and structure-activity relationship of a focused library of ?-phenylalanine derivatives as novel eEF2K inhibitors with apoptosis-inducing mechanisms in breast cancer.	causal interaction,therapeutic application,unassigned	3,4,0	
2.7.11.20	Breast Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29288948&form=6&db=m	Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy.	causal interaction,ongoing research,therapeutic application,unassigned	3,2,1,0	
2.7.11.20	Breast Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32027127&form=6&db=m	Design, Synthesis, and Molecular Modeling Studies of Novel Coumarin Carboxamide Derivatives as eEF-2K Inhibitors.	causal interaction,diagnostic usage,ongoing research,therapeutic application	4,3,4,1	
2.7.11.20	Breast Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32042799&form=6&db=m	eEF2 kinase mediated autophagy as a potential therapeutic target for paclitaxel-resistant triple-negative breast cancer.	causal interaction,diagnostic usage,ongoing research,therapeutic application	3,4,4,4	
2.7.11.20	Breast Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32717479&form=6&db=m	Designing an eEF2K-Targeting PROTAC small molecule that induces apoptosis in MDA-MB-231 cells.	causal interaction,therapeutic application,unassigned	3,1,0	
2.7.11.20	Breast Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33144562&form=6&db=m	Combined treatment of mitoxantrone sensitizes breast cancer cells to rapalogs through blocking eEF-2K-mediated activation of Akt and autophagy.	causal interaction,therapeutic application,unassigned	4,4,0	
2.7.11.20	Breast Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33779695&form=6&db=m	Elongation factor eEF2 kinase and autophagy jointly promote survival of cancer cells.	diagnostic usage,ongoing research,unassigned	3,3,0	
2.7.11.20	Breast Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33860211&form=6&db=m	Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth In Vivo.	causal interaction,ongoing research,therapeutic application,unassigned	4,4,4,0	
2.7.11.20	Breast Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33911160&form=6&db=m	Inhibition of eEF2K synergizes with glutaminase inhibitors or 4EBP1 depletion to suppress growth of triple-negative breast cancer cells.	causal interaction,therapeutic application,unassigned	3,4,0	
2.7.11.20	Breast Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34488125&form=6&db=m	Novel inhibitors of eukaryotic elongation factor 2 kinase: In silico, synthesis and in vitro studies.	causal interaction,diagnostic usage,ongoing research,therapeutic application	4,3,4,4	
2.7.11.20	Carcinogenesis	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16921268&form=6&db=m	Elongation factor-2 kinase: its role in protein synthesis and autophagy.	causal interaction,therapeutic application,unassigned	4,2,0	
2.7.11.20	Carcinogenesis	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24955726&form=6&db=m	Silencing of EEF2K (eukaryotic elongation factor-2 kinase) reveals AMPK-ULK1-dependent autophagy in colon cancer cells.	causal interaction,ongoing research,therapeutic application,unassigned	4,3,4,0	
2.7.11.20	Carcinogenesis	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25023961&form=6&db=m	Eukaryotic elongation factor-2 kinase (eEF2K): a potential therapeutic target in cancer.	causal interaction,therapeutic application,unassigned	4,4,0	
2.7.11.20	Carcinogenesis	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26918606&form=6&db=m	FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.	causal interaction,diagnostic usage,ongoing research,therapeutic application	4,2,4,1	
2.7.11.20	Carcinogenesis	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28036267&form=6&db=m	MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.	causal interaction,therapeutic application,unassigned	4,4,0	
2.7.11.20	Carcinogenesis	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28745127&form=6&db=m	Modified gold-based siRNA nanotherapeutics for targeted therapy of triple-negative breast cancer.	causal interaction,ongoing research,therapeutic application,unassigned	4,4,4,0	
2.7.11.20	Carcinogenesis	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29186827&form=6&db=m	Eukaryotic Elongation Factor 2 Kinase (eEF2K) in Cancer.	causal interaction,diagnostic usage,therapeutic application,unassigned	4,3,4,0	
2.7.11.20	Carcinogenesis	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30268477&form=6&db=m	Elongation factor-2 kinase (eEF-2K) expression is associated with poor patient survival and promotes proliferation, invasion and tumor growth of lung cancer.	causal interaction,diagnostic usage,ongoing research,therapeutic application	4,3,4,3	
2.7.11.20	Carcinogenesis	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32377852&form=6&db=m	Eukaryotic elongation factor-2 kinase (eEF2K) signaling in tumor and microenvironment as a novel molecular target.	causal interaction,diagnostic usage,ongoing research,therapeutic application	4,3,1,4	
2.7.11.20	Carcinogenesis	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34162208&form=6&db=m	Inhibiting Eukaryotic Elongation Factor 2 Kinase: An Update on Pharmacological Small-Molecule Compounds in Cancer.	causal interaction,therapeutic application,unassigned	4,4,0	
2.7.11.20	Carcinoma	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26893763&form=6&db=m	MicroRNA-877 acts as a tumor suppressor by directly targeting eEF2K in renal cell carcinoma.	therapeutic application,unassigned	1,0	
2.7.11.20	Carcinoma	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28431753&form=6&db=m	eEF2K promotes progression and radioresistance of esophageal squamous cell carcinoma.	causal interaction,diagnostic usage,ongoing research,therapeutic application	3,3,3,4	
2.7.11.20	Carcinoma, Hepatocellular	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28060762&form=6&db=m	Eukaryotic elongation factor 2 is a prognostic marker and its kinase a potential therapeutic target in HCC.	causal interaction,therapeutic application,unassigned	4,1,0	
2.7.11.20	Carcinoma, Hepatocellular	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29050305&form=6&db=m	Calyxin Y sensitizes cisplatin-sensitive and resistant hepatocellular carcinoma cells to cisplatin through apoptotic and autophagic cell death via SCF ?TrCP-mediated eEF2K degradation.	unassigned	-	
2.7.11.20	Carcinoma, Hepatocellular	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31286509&form=6&db=m	Eukaryotic elongation factor 2 kinase promotes angiogenesis in hepatocellular carcinoma via PI3K/Akt and STAT3.	causal interaction,ongoing research,therapeutic application,unassigned	4,3,3,0	
2.7.11.20	Carcinoma, Renal Cell	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26893763&form=6&db=m	MicroRNA-877 acts as a tumor suppressor by directly targeting eEF2K in renal cell carcinoma.	therapeutic application,unassigned	1,0	
2.7.11.20	Cardiomegaly	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33191388&form=6&db=m	Age-dependent increase in activity of eukaryotic elongation factor 2 kinase in mesenteric arteries from spontaneously hypertensive rats.	causal interaction,ongoing research,therapeutic application,unassigned	4,2,4,0	
2.7.11.20	Cardiovascular Diseases	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25069823&form=6&db=m	Eukaryotic elongation factor 2 kinase controls proliferation and migration of vascular smooth muscle cells.	causal interaction,therapeutic application,unassigned	4,4,0	
2.7.11.20	Colonic Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24955726&form=6&db=m	Silencing of EEF2K (eukaryotic elongation factor-2 kinase) reveals AMPK-ULK1-dependent autophagy in colon cancer cells.	causal interaction,ongoing research,therapeutic application,unassigned	4,3,4,0	
2.7.11.20	Colorectal Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22268531&form=6&db=m	The nonsteroidal anti-inflammatory drug indomethacin activates the eIF2alpha kinase PKR, causing a translational block in human colorectal cancer cells.	ongoing research,therapeutic application,unassigned	3,4,0	
2.7.11.20	Colorectal Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31266475&form=6&db=m	Eukaryotic elongation factor-2 kinase expression is an independent prognostic factor in colorectal cancer.	causal interaction,diagnostic usage,ongoing research,unassigned	4,4,3,0	
2.7.11.20	Cytomegalovirus Infections	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31636182&form=6&db=m	Repression of eEF2K transcription by NF-?B tunes translation elongation to inflammation and dsDNA-sensing.	unassigned	-	
2.7.11.20	Diabetes Mellitus, Type 2	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17991718&form=6&db=m	Regulation of elongation phase of mRNA translation in diabetic nephropathy: amelioration by rapamycin.	causal interaction,therapeutic application,unassigned	2,1,0	
2.7.11.20	elongation factor 2 kinase deficiency	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12897138&form=6&db=m	Phosphorylation of the alpha subunit of eukaryotic initiation factor 2 is required for activation of NF-kappaB in response to diverse cellular stresses.	causal interaction,diagnostic usage,therapeutic application,unassigned	1,3,1,0	
2.7.11.20	elongation factor 2 kinase deficiency	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18367482&form=6&db=m	Deficiency of heme-regulated eIF2alpha kinase decreases hepcidin expression and splenic iron in HFE-/- mice.	causal interaction,ongoing research,unassigned	4,4,0	
2.7.11.20	elongation factor 2 kinase deficiency	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27466362&form=6&db=m	Paradoxical Roles of Elongation Factor-2 Kinase in Stem Cell Survival.	causal interaction,diagnostic usage,unassigned	4,3,0	
2.7.11.20	Encephalitis	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30158316&form=6&db=m	Chemoproteomic Discovery of a Ritanserin-Targeted Kinase Network Mediating Apoptotic Cell Death of Lung Tumor Cells.	causal interaction,therapeutic application,unassigned	4,4,0	
2.7.11.20	Encephalomyelitis	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24362236&form=6&db=m	GCN2 kinase plays an important role triggering the remission phase of experimental autoimmune encephalomyelitis (EAE) in mice.	ongoing research,therapeutic application,unassigned	3,3,0	
2.7.11.20	Encephalomyelitis, Autoimmune, Experimental	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24362236&form=6&db=m	GCN2 kinase plays an important role triggering the remission phase of experimental autoimmune encephalomyelitis (EAE) in mice.	ongoing research,therapeutic application,unassigned	3,3,0	
2.7.11.20	Epilepsy	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27005990&form=6&db=m	eEF2K/eEF2 Pathway Controls the Excitation/Inhibition Balance and Susceptibility to Epileptic Seizures.	causal interaction,therapeutic application,unassigned	4,4,0	
2.7.11.20	Epilepsy	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32088293&form=6&db=m	Eukaryotic Elongation Factor 2 Kinase a Pharmacological Target to Regulate Protein Translation Dysfunction in Neurological Diseases.	causal interaction,therapeutic application,unassigned	4,4,0	
2.7.11.20	Esophageal Squamous Cell Carcinoma	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28431753&form=6&db=m	eEF2K promotes progression and radioresistance of esophageal squamous cell carcinoma.	causal interaction,diagnostic usage,ongoing research,therapeutic application	3,3,3,4	
2.7.11.20	Essential Hypertension	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33191388&form=6&db=m	Age-dependent increase in activity of eukaryotic elongation factor 2 kinase in mesenteric arteries from spontaneously hypertensive rats.	causal interaction,ongoing research,therapeutic application,unassigned	4,2,4,0	
2.7.11.20	Fetal Growth Retardation	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27317589&form=6&db=m	Intrauterine growth restriction inhibits expression of eukaryotic elongation factor 2 kinase, a regulator of protein translation.	ongoing research,therapeutic application,unassigned	3,1,0	
2.7.11.20	Fibrosarcoma	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30158316&form=6&db=m	Chemoproteomic Discovery of a Ritanserin-Targeted Kinase Network Mediating Apoptotic Cell Death of Lung Tumor Cells.	causal interaction,therapeutic application,unassigned	4,4,0	
2.7.11.20	Glioblastoma	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16540650&form=6&db=m	Elongation factor-2 kinase regulates autophagy in human glioblastoma cells.	causal interaction,diagnostic usage,ongoing research,therapeutic application	3,3,4,2	
2.7.11.20	Glioblastoma	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16921268&form=6&db=m	Elongation factor-2 kinase: its role in protein synthesis and autophagy.	causal interaction,therapeutic application,unassigned	4,2,0	
2.7.11.20	Glioblastoma	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21278783&form=6&db=m	Expression of elongation factor-2 kinase contributes to anoikis resistance and invasion of human glioma cells.	causal interaction,diagnostic usage,ongoing research,therapeutic application	3,4,4,3	
2.7.11.20	Glioblastoma	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23706743&form=6&db=m	The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation.	causal interaction,diagnostic usage,ongoing research,unassigned	3,3,4,0	
2.7.11.20	Glioblastoma	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24955726&form=6&db=m	Silencing of EEF2K (eukaryotic elongation factor-2 kinase) reveals AMPK-ULK1-dependent autophagy in colon cancer cells.	causal interaction,ongoing research,therapeutic application,unassigned	4,3,4,0	
2.7.11.20	Glioblastoma	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27626499&form=6&db=m	Rottlerin inhibits cell growth and invasion via down-regulation of Cdc20 in glioma cells.	therapeutic application,unassigned	1,0	
2.7.11.20	Glioma	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9056675&form=6&db=m	Effects of rottlerin, an inhibitor of calmodulin-dependent protein kinase III, on cellular proliferation, viability, and cell cycle distribution in malignant glioma cells.	causal interaction,ongoing research,therapeutic application,unassigned	4,4,1,0	
2.7.11.20	Glioma	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14583488&form=6&db=m	Identification and characterization of an inhibitor of eukaryotic elongation factor 2 kinase against human cancer cell lines.	causal interaction,ongoing research,therapeutic application,unassigned	1,4,4,0	
2.7.11.20	Glioma	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19244119&form=6&db=m	Silencing of elongation factor-2 kinase potentiates the effect of 2-deoxy-D-glucose against human glioma cells through blunting of autophagy.	causal interaction,ongoing research,therapeutic application,unassigned	3,4,4,0	
2.7.11.20	Glioma	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21278783&form=6&db=m	Expression of elongation factor-2 kinase contributes to anoikis resistance and invasion of human glioma cells.	causal interaction,diagnostic usage,ongoing research,therapeutic application	3,4,4,3	
2.7.11.20	Glioma	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21307130&form=6&db=m	eEF-2 Kinase Dictates Cross-Talk between Autophagy and Apoptosis Induced by Akt Inhibition, Thereby Modulating Cytotoxicity of Novel Akt Inhibitor MK-2206.	causal interaction,ongoing research,therapeutic application,unassigned	3,2,4,0	
2.7.11.20	Glioma	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21460616&form=6&db=m	eEF-2 kinase, another meddler in the "Yin and Yang" of Akt-mediated cell fate?	causal interaction,therapeutic application,unassigned	4,4,0	
2.7.11.20	Glioma	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21945617&form=6&db=m	Inhibition of eEF-2 kinase sensitizes human glioma cells to TRAIL and down-regulates Bcl-xL expression.	causal interaction,ongoing research,therapeutic application,unassigned	4,3,4,0	
2.7.11.20	Glioma	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22749997&form=6&db=m	Phosphorylation of elongation factor-2 kinase differentially regulates the enzyme's stability under stress conditions.	causal interaction,therapeutic application,unassigned	3,2,0	
2.7.11.20	Glioma	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24078616&form=6&db=m	High-Throughput Screens for eEF-2 Kinase.	causal interaction,therapeutic application,unassigned	4,4,0	
2.7.11.20	Glioma	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24303044&form=6&db=m	Inhibition of elongation factor-2 kinase augments the antitumor activity of Temozolomide against glioma.	causal interaction,ongoing research,therapeutic application,unassigned	3,4,4,0	
2.7.11.20	Herpes Simplex	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11756670&form=6&db=m	Regulation of starvation- and virus-induced autophagy by the eIF2alpha kinase signaling pathway.	therapeutic application,unassigned	1,0	
2.7.11.20	Herpes Simplex	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16874088&form=6&db=m	PKR-Dependent Autophagic Degradation of Herpes Simplex Virus Type 1.	therapeutic application,unassigned	1,0	
2.7.11.20	Hyperglycemia	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17991718&form=6&db=m	Regulation of elongation phase of mRNA translation in diabetic nephropathy: amelioration by rapamycin.	causal interaction,therapeutic application,unassigned	2,1,0	
2.7.11.20	Hypertension	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23812389&form=6&db=m	Eukaryotic elongation factor 2 kinase regulates the development of hypertension through oxidative stress-dependent vascular inflammation.	causal interaction,ongoing research,therapeutic application,unassigned	4,4,1,0	
2.7.11.20	Hypertension	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25069823&form=6&db=m	Eukaryotic elongation factor 2 kinase controls proliferation and migration of vascular smooth muscle cells.	causal interaction,therapeutic application,unassigned	4,4,0	
2.7.11.20	Hypertension	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25770246&form=6&db=m	Eukaryotic elongation factor 2 kinase mediates monocrotaline-induced pulmonary arterial hypertension via reactive oxygen species-dependent vascular remodeling.	causal interaction,ongoing research,therapeutic application,unassigned	1,2,2,0	
2.7.11.20	Hypertension	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26697749&form=6&db=m	Expression and localization of calmodulin-related proteins in brain, heart and kidney from spontaneously hypertensive rats.	causal interaction,ongoing research,unassigned	3,1,0	
2.7.11.20	Hypertension	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26806303&form=6&db=m	Eukaryotic elongation factor 2 kinase as a drug target in cancer, and in cardiovascular and neurodegenerative diseases.	causal interaction,therapeutic application,unassigned	3,1,0	
2.7.11.20	Hypertension	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30429409&form=6&db=m	Eukaryotic elongation factor 2 kinase inhibitor, A484954 inhibits noradrenaline-induced acute increase of blood pressure in rats.	causal interaction,ongoing research,unassigned	2,2,0	
2.7.11.20	Hypertension	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31484844&form=6&db=m	Eukaryotic elongation factor 2 kinase inhibitor, A484954 potentiates ?-adrenergic receptor agonist-induced acute decrease in diastolic blood pressure in rats.	causal interaction,unassigned	4,0	
2.7.11.20	Hypertension	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32088293&form=6&db=m	Eukaryotic Elongation Factor 2 Kinase a Pharmacological Target to Regulate Protein Translation Dysfunction in Neurological Diseases.	causal interaction,therapeutic application,unassigned	4,4,0	
2.7.11.20	Hypertension	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33191388&form=6&db=m	Age-dependent increase in activity of eukaryotic elongation factor 2 kinase in mesenteric arteries from spontaneously hypertensive rats.	causal interaction,ongoing research,therapeutic application,unassigned	4,2,4,0	
2.7.11.20	Hypertension, Pulmonary	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31202500&form=6&db=m	Unique wreath-like smooth muscle proliferation of the pulmonary vasculature in pulmonary veno-occlusive disease versus pulmonary arterial hypertension.	causal interaction,unassigned	4,0	
2.7.11.20	Infections	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15542627&form=6&db=m	Resistance to vesicular stomatitis virus infection requires a functional cross talk between the eukaryotic translation initiation factor 2alpha kinases PERK and PKR.	causal interaction,ongoing research,therapeutic application,unassigned	2,1,3,0	
2.7.11.20	Infections	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15890928&form=6&db=m	Human cytomegalovirus infection activates and regulates the unfolded protein response.	causal interaction,unassigned	3,0	
2.7.11.20	Infections	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19636416&form=6&db=m	Immune reactions against elongation factor 2 kinase: specific pathogenesis of gastric ulcer from Helicobacter pylori infection.	causal interaction,ongoing research,unassigned	1,3,0	
2.7.11.20	Influenza, Human	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19436736&form=6&db=m	P58: A Novel "CIHD" Member of the Host Innate Defense Response against Pathogenic Virus Infection.	therapeutic application,unassigned	2,0	
2.7.11.20	Influenza, Human	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19461876&form=6&db=m	P58(IPK): a novel "CIHD" member of the host innate defense response against pathogenic virus infection.	therapeutic application,unassigned	2,0	
2.7.11.20	Iron Deficiencies	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11726526&form=6&db=m	Heme-regulated eIF2alpha kinase (HRI) is required for translational regulation and survival of erythroid precursors in iron deficiency.	causal interaction,unassigned	3,0	
2.7.11.20	Iron Deficiencies	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17932563&form=6&db=m	The function of heme-regulated eIF2alpha kinase in murine iron homeostasis and macrophage maturation.	unassigned	-	
2.7.11.20	Iron Deficiencies	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18367482&form=6&db=m	Deficiency of heme-regulated eIF2alpha kinase decreases hepcidin expression and splenic iron in HFE-/- mice.	causal interaction,ongoing research,unassigned	4,4,0	
2.7.11.20	Iron Deficiencies	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18665838&form=6&db=m	Haem-regulated eIF2alpha kinase is necessary for adaptive gene expression in erythroid precursors under the stress of iron deficiency.	causal interaction,unassigned	2,0	
2.7.11.20	Iron Overload	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18367482&form=6&db=m	Deficiency of heme-regulated eIF2alpha kinase decreases hepcidin expression and splenic iron in HFE-/- mice.	causal interaction,ongoing research,unassigned	4,4,0	
2.7.11.20	Ischemic Attack, Transient	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12429199&form=6&db=m	Mechanisms underlying suppression of protein synthesis induced by transient focal cerebral ischemia in mouse brain.	causal interaction,therapeutic application,unassigned	3,3,0	
2.7.11.20	Liver Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31286509&form=6&db=m	Eukaryotic elongation factor 2 kinase promotes angiogenesis in hepatocellular carcinoma via PI3K/Akt and STAT3.	causal interaction,ongoing research,therapeutic application,unassigned	4,3,3,0	
2.7.11.20	Lung Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22352903&form=6&db=m	Investigating the Kinetic Mechanism of Inhibition of Elongation Factor 2 Kinase by NH125: Evidence of a Common in Vitro Artifact.	ongoing research,therapeutic application,unassigned	1,1,0	
2.7.11.20	Lung Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30268477&form=6&db=m	Elongation factor-2 kinase (eEF-2K) expression is associated with poor patient survival and promotes proliferation, invasion and tumor growth of lung cancer.	causal interaction,diagnostic usage,ongoing research,therapeutic application	4,3,4,3	
2.7.11.20	Lung Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32027127&form=6&db=m	Design, Synthesis, and Molecular Modeling Studies of Novel Coumarin Carboxamide Derivatives as eEF-2K Inhibitors.	causal interaction,diagnostic usage,ongoing research,therapeutic application	4,3,4,1	
2.7.11.20	Lung Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32054489&form=6&db=m	The eEF2 kinase-induced STAT3 inactivation inhibits lung cancer cell proliferation by phosphorylation of PKM2.	causal interaction,ongoing research,unassigned	4,4,0	
2.7.11.20	Lung Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32377852&form=6&db=m	Eukaryotic elongation factor-2 kinase (eEF2K) signaling in tumor and microenvironment as a novel molecular target.	causal interaction,diagnostic usage,ongoing research,therapeutic application	4,3,1,4	
2.7.11.20	Lung Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33094805&form=6&db=m	eEF2K enhances expression of PD-L1 by promoting the translation of its mRNA.	causal interaction,diagnostic usage,unassigned	3,4,0	
2.7.11.20	Lung Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34159079&form=6&db=m	Eef2k is not required for fertility in male mice.	causal interaction,diagnostic usage,unassigned	3,3,0	
2.7.11.20	Lymphatic Metastasis	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34352439&form=6&db=m	eEF2K as a novel metastatic and prognostic biomarker in gastric cancer patients.	causal interaction,diagnostic usage,ongoing research,therapeutic application	2,4,4,3	
2.7.11.20	Malnutrition	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16246168&form=6&db=m	Coping with stress: eIF2 kinases and translational control.	ongoing research,unassigned	2,0	
2.7.11.20	Medulloblastoma	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23706743&form=6&db=m	The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation.	causal interaction,diagnostic usage,ongoing research,unassigned	3,3,4,0	
2.7.11.20	Medulloblastoma	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26835355&form=6&db=m	Energy metabolism in neurodevelopment and medulloblastoma.	causal interaction,therapeutic application,unassigned	1,1,0	
2.7.11.20	Melanoma	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30914761&form=6&db=m	Eukaryotic elongation factor-2 kinase regulates the cross-talk between autophagy and pyroptosis in doxorubicin-treated human melanoma cells in vitro.	causal interaction,diagnostic usage,ongoing research,therapeutic application	3,3,4,2	
2.7.11.20	Memory Disorders	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30667373&form=6&db=m	Genetic reduction of eEF2 kinase alleviates pathophysiology in Alzheimer's disease model mice.	causal interaction,ongoing research,therapeutic application,unassigned	4,2,1,0	
2.7.11.20	Nasopharyngeal Carcinoma	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27756261&form=6&db=m	Inhibition of eEF-2 kinase sensitizes human nasopharyngeal carcinoma cells to lapatinib-induced apoptosis through the Src and Erk pathways.	causal interaction,diagnostic usage,ongoing research,therapeutic application	3,2,4,2	
2.7.11.20	Nasopharyngeal Carcinoma	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27785067&form=6&db=m	Everolimus enhances cellular cytotoxicity of lapatinib via the eukaryotic elongation factor-2 kinase pathway in nasopharyngeal carcinoma cells.	ongoing research,unassigned	1,0	
2.7.11.20	Neoplasm Metastasis	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29235102&form=6&db=m	Eukaryotic elongation factor 2 kinase upregulates the expression of proteins implicated in cell migration and cancer cell metastasis.	causal interaction,diagnostic usage,ongoing research,unassigned	4,2,2,0	
2.7.11.20	Neoplasm Metastasis	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33539938&form=6&db=m	Targeting eukaryotic elongation factor-2 kinase suppresses the growth and peritoneal metastasis of ovarian cancer.	causal interaction,diagnostic usage,unassigned	1,1,0	
2.7.11.20	Neoplasm Metastasis	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33673713&form=6&db=m	Progress in the Development of Eukaryotic Elongation Factor 2 Kinase (eEF2K) Natural Product and Synthetic Small Molecule Inhibitors for Cancer Chemotherapy.	causal interaction,therapeutic application,unassigned	4,4,0	
2.7.11.20	Neoplasm Metastasis	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34352439&form=6&db=m	eEF2K as a novel metastatic and prognostic biomarker in gastric cancer patients.	causal interaction,diagnostic usage,ongoing research,therapeutic application	2,4,4,3	
2.7.11.20	Neoplasm Metastasis	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34488125&form=6&db=m	Novel inhibitors of eukaryotic elongation factor 2 kinase: In silico, synthesis and in vitro studies.	causal interaction,diagnostic usage,ongoing research,therapeutic application	4,3,4,4	
2.7.11.20	Neoplasm, Residual	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32042799&form=6&db=m	eEF2 kinase mediated autophagy as a potential therapeutic target for paclitaxel-resistant triple-negative breast cancer.	causal interaction,diagnostic usage,ongoing research,therapeutic application	3,4,4,4	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11101152&form=6&db=m	Cloning of hHRI, human heme-regulated eukaryotic initiation factor 2alpha kinase: down-regulated in epithelial ovarian cancers.	causal interaction,unassigned	2,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11333223&form=6&db=m	Minimum requirements for the function of eukaryotic translation initiation factor 2.	unassigned	-	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12051769&form=6&db=m	Detection of anti-elongation factor 2 kinase (calmodulin-dependent protein kinase III) antibodies in patients with systemic lupus erythematosus.	causal interaction,therapeutic application,unassigned	4,4,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12171600&form=6&db=m	Stress-induced regulation of eukaryotic elongation factor 2 kinase by SB 203580-sensitive and -insensitive pathways.	ongoing research,therapeutic application,unassigned	4,1,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14583488&form=6&db=m	Identification and characterization of an inhibitor of eukaryotic elongation factor 2 kinase against human cancer cell lines.	causal interaction,ongoing research,therapeutic application,unassigned	1,4,4,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15322237&form=6&db=m	P-glycoprotein mediates resistance to histidine kinase inhibitors.	ongoing research,therapeutic application,unassigned	2,4,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15867377&form=6&db=m	Identification of the ubiquitin-proteasome pathway in the regulation of the stability of eukaryotic elongation factor-2 kinase.	therapeutic application,unassigned	2,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16540650&form=6&db=m	Elongation factor-2 kinase regulates autophagy in human glioblastoma cells.	causal interaction,diagnostic usage,ongoing research,therapeutic application	3,3,4,2	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16921268&form=6&db=m	Elongation factor-2 kinase: its role in protein synthesis and autophagy.	causal interaction,therapeutic application,unassigned	4,2,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19244119&form=6&db=m	Silencing of elongation factor-2 kinase potentiates the effect of 2-deoxy-D-glucose against human glioma cells through blunting of autophagy.	causal interaction,ongoing research,therapeutic application,unassigned	3,4,4,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19360331&form=6&db=m	Overexpression of eukaryotic elongation factor eEF2 in gastrointestinal cancers and its involvement in G2/M progression in the cell cycle.	causal interaction,unassigned	2,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20596679&form=6&db=m	Sensitivity of doxorubicin-resistant cells to sorafenib: possible role for inhibition of eukaryotic initiation factor-2alpha phosphorylation.	causal interaction,therapeutic application,unassigned	1,4,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21278783&form=6&db=m	Expression of elongation factor-2 kinase contributes to anoikis resistance and invasion of human glioma cells.	causal interaction,diagnostic usage,ongoing research,therapeutic application	3,4,4,3	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21460616&form=6&db=m	eEF-2 kinase, another meddler in the "Yin and Yang" of Akt-mediated cell fate?	causal interaction,therapeutic application,unassigned	4,4,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21605678&form=6&db=m	Purification and characterization of tagless recombinant human elongation factor 2 kinase (eEF-2K) expressed in Escherichia coli.	causal interaction,unassigned	1,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21945617&form=6&db=m	Inhibition of eEF-2 kinase sensitizes human glioma cells to TRAIL and down-regulates Bcl-xL expression.	causal interaction,ongoing research,therapeutic application,unassigned	4,3,4,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22020937&form=6&db=m	1-Benzyl-3-cetyl-2-methylimidazolium iodide (NH125) induces phosphorylation of eukaryotic elongation factor-2 (eEF2): a cautionary note on the anticancer mechanism of an eEF2 kinase inhibitor.	therapeutic application,unassigned	4,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22123175&form=6&db=m	The combination of tephrosin with 2-deoxy-D-glucose enhances the cytotoxicity via accelerating ATP depletion and blunting autophagy in human cancer cells.	ongoing research,unassigned	2,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22749997&form=6&db=m	Phosphorylation of elongation factor-2 kinase differentially regulates the enzyme's stability under stress conditions.	causal interaction,therapeutic application,unassigned	3,2,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22911754&form=6&db=m	Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to Doxorubicin in an orthotopic model of breast cancer.	causal interaction,ongoing research,therapeutic application,unassigned	4,3,4,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22932089&form=6&db=m	Roles of eEF-2 kinase in cancer.	diagnostic usage,unassigned	3,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23182879&form=6&db=m	Integrated regulation of autophagy and apoptosis by EEF2K controls cellular fate and modulates the efficacy of curcumin and velcade against tumor cells.	causal interaction,ongoing research,therapeutic application,unassigned	2,3,1,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23706743&form=6&db=m	The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation.	causal interaction,diagnostic usage,ongoing research,unassigned	3,3,4,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23763997&form=6&db=m	Adaptation to starvation: translating a matter of life or death.	unassigned	-	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24193916&form=6&db=m	Targeting elongation factor-2 kinase (eEF-2K) induces apoptosis in human pancreatic cancer cells.	causal interaction,diagnostic usage,ongoing research,therapeutic application	3,2,4,1	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24732796&form=6&db=m	A conserved loop in the catalytic domain of eukaryotic elongation factor 2 kinase plays a key role in its substrate specificity.	causal interaction,unassigned	3,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24853390&form=6&db=m	Eukaryotic elongation factor 2 kinase, an unusual enzyme with multiple roles.	therapeutic application,unassigned	1,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24891364&form=6&db=m	Surviving metabolic stress: of mice (squirrels) and men.	unassigned	-	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24955726&form=6&db=m	Silencing of EEF2K (eukaryotic elongation factor-2 kinase) reveals AMPK-ULK1-dependent autophagy in colon cancer cells.	causal interaction,ongoing research,therapeutic application,unassigned	4,3,4,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25023961&form=6&db=m	Eukaryotic elongation factor-2 kinase (eEF2K): a potential therapeutic target in cancer.	causal interaction,therapeutic application,unassigned	4,4,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25182533&form=6&db=m	Eukaryotic elongation factor 2 kinase activity is controlled by multiple inputs from oncogenic signaling.	causal interaction,unassigned	3,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25215932&form=6&db=m	Elongation factor-2 kinase regulates TG2/?1 integrin/Src/uPAR pathway and epithelial-mesenchymal transition mediating pancreatic cancer cells invasion.	causal interaction,ongoing research,therapeutic application,unassigned	4,1,4,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25224652&form=6&db=m	Reversible covalent inhibition of eEF-2K by carbonitriles.	causal interaction,therapeutic application,unassigned	3,4,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25244326&form=6&db=m	How does oncogene transformation render tumor cells hypersensitive to nutrient deprivation?	therapeutic application,unassigned	4,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25248493&form=6&db=m	Eukaryotic elongation factor 2 kinase confers tolerance to stress conditions in cancer cells.	causal interaction,therapeutic application,unassigned	3,4,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25330770&form=6&db=m	Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K.	causal interaction,ongoing research,therapeutic application,unassigned	2,2,2,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25464034&form=6&db=m	Stress-mediated translational control in cancer cells.	ongoing research,unassigned	4,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25475470&form=6&db=m	Impairing eukaryotic elongation factor 2 kinase activity decreases atherosclerotic plaque formation.	causal interaction,ongoing research,therapeutic application,unassigned	4,4,4,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25670349&form=6&db=m	Regulated stability of eukaryotic elongation factor 2 kinase requires intrinsic but not ongoing activity.	ongoing research,therapeutic application,unassigned	3,4,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25755286&form=6&db=m	Elongation factor 2 kinase is regulated by proline hydroxylation and protects cells during hypoxia.	causal interaction,therapeutic application,unassigned	3,3,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25776553&form=6&db=m	Molecular Mechanism for the Control of Eukaryotic Elongation Factor 2 Kinase by pH: Role in Cancer Cell Survival.	causal interaction,diagnostic usage,ongoing research,therapeutic application	3,4,4,2	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26009171&form=6&db=m	Regulation and roles of elongation factor 2 kinase.	therapeutic application,unassigned	2,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26501899&form=6&db=m	Application of Eukaryotic Elongation Factor-2 Kinase (eEF-2K) for Cancer Therapy: Expression, Purification, and High-Throughput Inhibitor Screening.	unassigned	-	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26552140&form=6&db=m	[Eukaryotic elongation factor 2 kinase and cancer].	causal interaction,therapeutic application,unassigned	4,4,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26776155&form=6&db=m	Integrative bioinformatics and proteomics-based discovery of an eEF2K inhibitor (cefatrizine) with ER stress modulation in breast cancer cells.	causal interaction,ongoing research,therapeutic application,unassigned	4,2,4,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26795954&form=6&db=m	Elongation factor 2 kinase promotes cell survival by inhibiting protein synthesis without inducing autophagy.	causal interaction,therapeutic application,unassigned	3,1,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26806303&form=6&db=m	Eukaryotic elongation factor 2 kinase as a drug target in cancer, and in cardiovascular and neurodegenerative diseases.	causal interaction,therapeutic application,unassigned	3,1,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26893763&form=6&db=m	MicroRNA-877 acts as a tumor suppressor by directly targeting eEF2K in renal cell carcinoma.	therapeutic application,unassigned	1,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26918606&form=6&db=m	FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.	causal interaction,diagnostic usage,ongoing research,therapeutic application	4,2,4,1	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27181208&form=6&db=m	eEF-2 kinase is a critical regulator of Warburg effect through controlling PP2A-A synthesis.	causal interaction,ongoing research,therapeutic application,unassigned	4,4,1,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27466362&form=6&db=m	Paradoxical Roles of Elongation Factor-2 Kinase in Stem Cell Survival.	causal interaction,diagnostic usage,unassigned	4,3,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27572820&form=6&db=m	Pharmacological eEF2K activation promotes cell death and inhibits cancer progression.	ongoing research,therapeutic application,unassigned	3,1,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27756261&form=6&db=m	Inhibition of eEF-2 kinase sensitizes human nasopharyngeal carcinoma cells to lapatinib-induced apoptosis through the Src and Erk pathways.	causal interaction,diagnostic usage,ongoing research,therapeutic application	3,2,4,2	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27818922&form=6&db=m	A high-throughput screening assay for eukaryotic elongation factor 2 kinase inhibitors.	diagnostic usage,ongoing research,therapeutic application,unassigned	2,4,2,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28036267&form=6&db=m	MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.	causal interaction,therapeutic application,unassigned	4,4,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28060762&form=6&db=m	Eukaryotic elongation factor 2 is a prognostic marker and its kinase a potential therapeutic target in HCC.	causal interaction,therapeutic application,unassigned	4,1,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28431753&form=6&db=m	eEF2K promotes progression and radioresistance of esophageal squamous cell carcinoma.	causal interaction,diagnostic usage,ongoing research,therapeutic application	3,3,3,4	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28502587&form=6&db=m	Direct and indirect activation of eukaryotic elongation factor 2 kinase by AMP-activated protein kinase.	causal interaction,unassigned	1,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28574509&form=6&db=m	MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation.	causal interaction,ongoing research,unassigned	4,4,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28745127&form=6&db=m	Modified gold-based siRNA nanotherapeutics for targeted therapy of triple-negative breast cancer.	causal interaction,ongoing research,therapeutic application,unassigned	4,4,4,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29186827&form=6&db=m	Eukaryotic Elongation Factor 2 Kinase (eEF2K) in Cancer.	causal interaction,diagnostic usage,therapeutic application,unassigned	4,3,4,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29235102&form=6&db=m	Eukaryotic elongation factor 2 kinase upregulates the expression of proteins implicated in cell migration and cancer cell metastasis.	causal interaction,diagnostic usage,ongoing research,unassigned	4,2,2,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29288948&form=6&db=m	Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy.	causal interaction,ongoing research,therapeutic application,unassigned	3,2,1,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29331413&form=6&db=m	eEF-2 Kinase-targeted miR-449b confers radiation sensitivity to cancer cells.	ongoing research,unassigned	3,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29748184&form=6&db=m	Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion.	causal interaction,diagnostic usage,therapeutic application,unassigned	4,1,4,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29971628&form=6&db=m	Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.	causal interaction,diagnostic usage,ongoing research,therapeutic application	4,1,3,4	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30158316&form=6&db=m	Chemoproteomic Discovery of a Ritanserin-Targeted Kinase Network Mediating Apoptotic Cell Death of Lung Tumor Cells.	causal interaction,therapeutic application,unassigned	4,4,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30214154&form=6&db=m	Inhibiting eEF-2 kinase-mediated autophagy enhanced the cytocidal effect of AKT inhibitor on human nasopharyngeal carcinoma.	therapeutic application,unassigned	4,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30268477&form=6&db=m	Elongation factor-2 kinase (eEF-2K) expression is associated with poor patient survival and promotes proliferation, invasion and tumor growth of lung cancer.	causal interaction,diagnostic usage,ongoing research,therapeutic application	4,3,4,3	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30880628&form=6&db=m	Structure prediction of eukaryotic elongation factor-2 kinase and identification of the binding mechanisms of its inhibitors: Homology modeling, Molecular Docking and Molecular Dynamics Simulation.	causal interaction,therapeutic application,unassigned	4,1,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30890561&form=6&db=m	Ablation of elongation factor 2 kinase enhances heat-shock protein 90 chaperone expression and protects cells under proteotoxic stress.	causal interaction,ongoing research,therapeutic application,unassigned	1,4,1,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30914761&form=6&db=m	Eukaryotic elongation factor-2 kinase regulates the cross-talk between autophagy and pyroptosis in doxorubicin-treated human melanoma cells in vitro.	causal interaction,diagnostic usage,ongoing research,therapeutic application	3,3,4,2	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31226250&form=6&db=m	What is the impact of eukaryotic elongation factor 2 kinase on cancer: A systematic review.	causal interaction,diagnostic usage,ongoing research,therapeutic application	3,1,3,4	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31266475&form=6&db=m	Eukaryotic elongation factor-2 kinase expression is an independent prognostic factor in colorectal cancer.	causal interaction,diagnostic usage,ongoing research,unassigned	4,4,3,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31286509&form=6&db=m	Eukaryotic elongation factor 2 kinase promotes angiogenesis in hepatocellular carcinoma via PI3K/Akt and STAT3.	causal interaction,ongoing research,therapeutic application,unassigned	4,3,3,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32027127&form=6&db=m	Design, Synthesis, and Molecular Modeling Studies of Novel Coumarin Carboxamide Derivatives as eEF-2K Inhibitors.	causal interaction,diagnostic usage,ongoing research,therapeutic application	4,3,4,1	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32042799&form=6&db=m	eEF2 kinase mediated autophagy as a potential therapeutic target for paclitaxel-resistant triple-negative breast cancer.	causal interaction,diagnostic usage,ongoing research,therapeutic application	3,4,4,4	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32054489&form=6&db=m	The eEF2 kinase-induced STAT3 inactivation inhibits lung cancer cell proliferation by phosphorylation of PKM2.	causal interaction,ongoing research,unassigned	4,4,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32088293&form=6&db=m	Eukaryotic Elongation Factor 2 Kinase a Pharmacological Target to Regulate Protein Translation Dysfunction in Neurological Diseases.	causal interaction,therapeutic application,unassigned	4,4,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32377852&form=6&db=m	Eukaryotic elongation factor-2 kinase (eEF2K) signaling in tumor and microenvironment as a novel molecular target.	causal interaction,diagnostic usage,ongoing research,therapeutic application	4,3,1,4	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32565934&form=6&db=m	AMPK decreases ERK1/2 activity and cancer cell sensitivity to nutrition deprivation by mediating a positive feedback loop involving eEF2K.	diagnostic usage,ongoing research,therapeutic application,unassigned	1,2,1,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33094805&form=6&db=m	eEF2K enhances expression of PD-L1 by promoting the translation of its mRNA.	causal interaction,diagnostic usage,unassigned	3,4,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33144562&form=6&db=m	Combined treatment of mitoxantrone sensitizes breast cancer cells to rapalogs through blocking eEF-2K-mediated activation of Akt and autophagy.	causal interaction,therapeutic application,unassigned	4,4,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33673713&form=6&db=m	Progress in the Development of Eukaryotic Elongation Factor 2 Kinase (eEF2K) Natural Product and Synthetic Small Molecule Inhibitors for Cancer Chemotherapy.	causal interaction,therapeutic application,unassigned	4,4,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33765606&form=6&db=m	Recent progress in agents targeting polo-like kinases: Promising therapeutic strategies.	causal interaction,therapeutic application,unassigned	1,4,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33779695&form=6&db=m	Elongation factor eEF2 kinase and autophagy jointly promote survival of cancer cells.	diagnostic usage,ongoing research,unassigned	3,3,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33860211&form=6&db=m	Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth In Vivo.	causal interaction,ongoing research,therapeutic application,unassigned	4,4,4,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33911160&form=6&db=m	Inhibition of eEF2K synergizes with glutaminase inhibitors or 4EBP1 depletion to suppress growth of triple-negative breast cancer cells.	causal interaction,therapeutic application,unassigned	3,4,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34065377&form=6&db=m	Discovery of Novel eEF2K Inhibitors Using HTS Fingerprint Generated from Predicted Profiling of Compound-Protein Interactions.	unassigned	-	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34162208&form=6&db=m	Inhibiting Eukaryotic Elongation Factor 2 Kinase: An Update on Pharmacological Small-Molecule Compounds in Cancer.	causal interaction,therapeutic application,unassigned	4,4,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34257429&form=6&db=m	eEF2K: an atypical kinase target for cancer.	causal interaction,therapeutic application,unassigned	4,4,0	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34352439&form=6&db=m	eEF2K as a novel metastatic and prognostic biomarker in gastric cancer patients.	causal interaction,diagnostic usage,ongoing research,therapeutic application	2,4,4,3	
2.7.11.20	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34488125&form=6&db=m	Novel inhibitors of eukaryotic elongation factor 2 kinase: In silico, synthesis and in vitro studies.	causal interaction,diagnostic usage,ongoing research,therapeutic application	4,3,4,4	
2.7.11.20	Nervous System Diseases	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26806303&form=6&db=m	Eukaryotic elongation factor 2 kinase as a drug target in cancer, and in cardiovascular and neurodegenerative diseases.	causal interaction,therapeutic application,unassigned	3,1,0	
2.7.11.20	Nervous System Diseases	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32088293&form=6&db=m	Eukaryotic Elongation Factor 2 Kinase a Pharmacological Target to Regulate Protein Translation Dysfunction in Neurological Diseases.	causal interaction,therapeutic application,unassigned	4,4,0	
2.7.11.20	Neuroblastoma	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28574509&form=6&db=m	MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation.	causal interaction,ongoing research,unassigned	4,4,0	
2.7.11.20	Neuroblastoma	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32892352&form=6&db=m	Bicuculline regulated protein synthesis is dependent on Homer1 and promotes its interaction with eEF2K through mTORC1-dependent phosphorylation.	ongoing research,unassigned	4,0	
2.7.11.20	Neurodegenerative Diseases	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26806303&form=6&db=m	Eukaryotic elongation factor 2 kinase as a drug target in cancer, and in cardiovascular and neurodegenerative diseases.	causal interaction,therapeutic application,unassigned	3,1,0	
2.7.11.20	Neurodegenerative Diseases	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32088293&form=6&db=m	Eukaryotic Elongation Factor 2 Kinase a Pharmacological Target to Regulate Protein Translation Dysfunction in Neurological Diseases.	causal interaction,therapeutic application,unassigned	4,4,0	
2.7.11.20	Neurodegenerative Diseases	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34065377&form=6&db=m	Discovery of Novel eEF2K Inhibitors Using HTS Fingerprint Generated from Predicted Profiling of Compound-Protein Interactions.	unassigned	-	
2.7.11.20	Ovarian Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33539938&form=6&db=m	Targeting eukaryotic elongation factor-2 kinase suppresses the growth and peritoneal metastasis of ovarian cancer.	causal interaction,diagnostic usage,unassigned	1,1,0	
2.7.11.20	Ovarian Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34488125&form=6&db=m	Novel inhibitors of eukaryotic elongation factor 2 kinase: In silico, synthesis and in vitro studies.	causal interaction,diagnostic usage,ongoing research,therapeutic application	4,3,4,4	
2.7.11.20	Pancreatic Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24193916&form=6&db=m	Targeting elongation factor-2 kinase (eEF-2K) induces apoptosis in human pancreatic cancer cells.	causal interaction,diagnostic usage,ongoing research,therapeutic application	3,2,4,1	
2.7.11.20	Pancreatic Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25215932&form=6&db=m	Elongation factor-2 kinase regulates TG2/?1 integrin/Src/uPAR pathway and epithelial-mesenchymal transition mediating pancreatic cancer cells invasion.	causal interaction,ongoing research,therapeutic application,unassigned	4,1,4,0	
2.7.11.20	Parkinson Disease	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29961428&form=6&db=m	Activity of translation regulator eukaryotic elongation factor-2 kinase is increased in Parkinson disease brain and its inhibition reduces alpha synuclein toxicity.	causal interaction,unassigned	4,0	
2.7.11.20	Prostatic Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33779695&form=6&db=m	Elongation factor eEF2 kinase and autophagy jointly promote survival of cancer cells.	diagnostic usage,ongoing research,unassigned	3,3,0	
2.7.11.20	Protoporphyria, Erythropoietic	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15931390&form=6&db=m	Heme-regulated eIF2alpha kinase modifies the phenotypic severity of murine models of erythropoietic protoporphyria and beta-thalassemia.	causal interaction,unassigned	2,0	
2.7.11.20	Pulmonary Arterial Hypertension	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25770246&form=6&db=m	Eukaryotic elongation factor 2 kinase mediates monocrotaline-induced pulmonary arterial hypertension via reactive oxygen species-dependent vascular remodeling.	causal interaction,ongoing research,therapeutic application,unassigned	1,2,2,0	
2.7.11.20	Pulmonary Arterial Hypertension	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26806303&form=6&db=m	Eukaryotic elongation factor 2 kinase as a drug target in cancer, and in cardiovascular and neurodegenerative diseases.	causal interaction,therapeutic application,unassigned	3,1,0	
2.7.11.20	Pulmonary Arterial Hypertension	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32088293&form=6&db=m	Eukaryotic Elongation Factor 2 Kinase a Pharmacological Target to Regulate Protein Translation Dysfunction in Neurological Diseases.	causal interaction,therapeutic application,unassigned	4,4,0	
2.7.11.20	Pulmonary Arterial Hypertension	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33191388&form=6&db=m	Age-dependent increase in activity of eukaryotic elongation factor 2 kinase in mesenteric arteries from spontaneously hypertensive rats.	causal interaction,ongoing research,therapeutic application,unassigned	4,2,4,0	
2.7.11.20	Pulmonary Veno-Occlusive Disease	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31202500&form=6&db=m	Unique wreath-like smooth muscle proliferation of the pulmonary vasculature in pulmonary veno-occlusive disease versus pulmonary arterial hypertension.	causal interaction,unassigned	4,0	
2.7.11.20	Starvation	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1448107&form=6&db=m	Mutations activating the yeast eIF-2 alpha kinase GCN2: isolation of alleles altering the domain related to histidyl-tRNA synthetases.	therapeutic application,unassigned	2,0	
2.7.11.20	Starvation	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7623840&form=6&db=m	The histidyl-tRNA synthetase-related sequence in the eIF-2 alpha protein kinase GCN2 interacts with tRNA and is required for activation in response to starvation for different amino acids.	ongoing research,unassigned	1,0	
2.7.11.20	Starvation	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8497269&form=6&db=m	GCN1, a translational activator of GCN4 in Saccharomyces cerevisiae, is required for phosphorylation of eukaryotic translation initiation factor 2 by protein kinase GCN2.	causal interaction,therapeutic application,unassigned	1,1,0	
2.7.11.20	Starvation	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9234705&form=6&db=m	Evidence that GCN1 and GCN20, translational regulators of GCN4, function on elongating ribosomes in activation of eIF2alpha kinase GCN2.	unassigned	-	
2.7.11.20	Starvation	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11408481&form=6&db=m	The protein kinase Gcn2p mediates sodium toxicity in yeast.	unassigned	-	
2.7.11.20	Starvation	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11781318&form=6&db=m	Translation mediated by the internal ribosome entry site of the cat-1 mRNA is regulated by glucose availability in a PERK kinase-dependent manner.	unassigned	-	
2.7.11.20	Starvation	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12697064&form=6&db=m	IfkA, a presumptive eIF2 alpha kinase of Dictyostelium, is required for proper timing of aggregation and regulation of mound size.	causal interaction,unassigned	2,0	
2.7.11.20	Starvation	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17023580&form=6&db=m	L-arginine availability regulates T-lymphocyte cell-cycle progression.	causal interaction,unassigned	4,0	
2.7.11.20	Starvation	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18249572&form=6&db=m	Basal expression of the Aspergillus fumigatus transcriptional activator CpcA is sufficient to support pulmonary aspergillosis.	therapeutic application,unassigned	1,0	
2.7.11.20	Starvation	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18337751&form=6&db=m	cdc2-cyclin B regulates eEF2 kinase activity in a cell cycle- and amino acid-dependent manner.	unassigned	-	
2.7.11.20	Starvation	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19221463&form=6&db=m	A critical role of eEF-2K in mediating autophagy in response to multiple cellular stresses.	therapeutic application,unassigned	2,0	
2.7.11.20	Starvation	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20404097&form=6&db=m	Snf1 promotes eIF2{alpha} phosphorylation by activating Gcn2 and inhibiting phosphatases Glc7 and Sit4.	causal interaction,unassigned	1,0	
2.7.11.20	Starvation	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20889542&form=6&db=m	L-arginine deprivation regulates cyclin D3 mRNA stability in human T cells by controlling HuR expression.	causal interaction,unassigned	1,0	
2.7.11.20	Starvation	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22704617&form=6&db=m	Amino acid starvation induced by invasive bacterial pathogens triggers an innate host defense program.	unassigned	-	
2.7.11.20	Starvation	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24853390&form=6&db=m	Eukaryotic elongation factor 2 kinase, an unusual enzyme with multiple roles.	therapeutic application,unassigned	1,0	
2.7.11.20	Starvation	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25182533&form=6&db=m	Eukaryotic elongation factor 2 kinase activity is controlled by multiple inputs from oncogenic signaling.	causal interaction,unassigned	3,0	
2.7.11.20	Starvation	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26009171&form=6&db=m	Regulation and roles of elongation factor 2 kinase.	therapeutic application,unassigned	2,0	
2.7.11.20	Starvation	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26795954&form=6&db=m	Elongation factor 2 kinase promotes cell survival by inhibiting protein synthesis without inducing autophagy.	causal interaction,therapeutic application,unassigned	3,1,0	
2.7.11.20	Starvation	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28767324&form=6&db=m	eEF2K protects MYCN-amplified cells from starvation.	causal interaction,ongoing research,unassigned	1,2,0	
2.7.11.20	Starvation	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28771613&form=6&db=m	Activation of Gcn2 in response to different stresses.	causal interaction,therapeutic application,unassigned	1,1,0	
2.7.11.20	Starvation	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31868900&form=6&db=m	The structure of human GCN2 reveals a parallel, back-to-back kinase dimer with a plastic DFG activation loop motif.	ongoing research,unassigned	1,0	
2.7.11.20	Starvation	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32016368&form=6&db=m	The molecular aetiology of tRNA synthetase depletion: induction of a GCN4 amino acid starvation response despite homeostatic maintenance of charged tRNA levels.	ongoing research,unassigned	1,0	
2.7.11.20	Starvation	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33779695&form=6&db=m	Elongation factor eEF2 kinase and autophagy jointly promote survival of cancer cells.	diagnostic usage,ongoing research,unassigned	3,3,0	
2.7.11.20	Starvation	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33911160&form=6&db=m	Inhibition of eEF2K synergizes with glutaminase inhibitors or 4EBP1 depletion to suppress growth of triple-negative breast cancer cells.	causal interaction,therapeutic application,unassigned	3,4,0	
2.7.11.20	Starvation	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34004054&form=6&db=m	Activation of GCN2 in macrophages promotes white adipose tissue browning and lipolysis under leucine deprivation.	unassigned	-	
2.7.11.20	Stomach Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34352439&form=6&db=m	eEF2K as a novel metastatic and prognostic biomarker in gastric cancer patients.	causal interaction,diagnostic usage,ongoing research,therapeutic application	2,4,4,3	
2.7.11.20	Stomach Ulcer	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19636416&form=6&db=m	Immune reactions against elongation factor 2 kinase: specific pathogenesis of gastric ulcer from Helicobacter pylori infection.	causal interaction,ongoing research,unassigned	1,3,0	
2.7.11.20	Triple Negative Breast Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25330770&form=6&db=m	Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K.	causal interaction,ongoing research,therapeutic application,unassigned	2,2,2,0	
2.7.11.20	Triple Negative Breast Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26918606&form=6&db=m	FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.	causal interaction,diagnostic usage,ongoing research,therapeutic application	4,2,4,1	
2.7.11.20	Triple Negative Breast Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28036267&form=6&db=m	MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.	causal interaction,therapeutic application,unassigned	4,4,0	
2.7.11.20	Triple Negative Breast Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28745127&form=6&db=m	Modified gold-based siRNA nanotherapeutics for targeted therapy of triple-negative breast cancer.	causal interaction,ongoing research,therapeutic application,unassigned	4,4,4,0	
2.7.11.20	Triple Negative Breast Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29971628&form=6&db=m	Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.	causal interaction,diagnostic usage,ongoing research,therapeutic application	4,1,3,4	
2.7.11.20	Triple Negative Breast Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30880628&form=6&db=m	Structure prediction of eukaryotic elongation factor-2 kinase and identification of the binding mechanisms of its inhibitors: Homology modeling, Molecular Docking and Molecular Dynamics Simulation.	causal interaction,therapeutic application,unassigned	4,1,0	
2.7.11.20	Triple Negative Breast Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32042799&form=6&db=m	eEF2 kinase mediated autophagy as a potential therapeutic target for paclitaxel-resistant triple-negative breast cancer.	causal interaction,diagnostic usage,ongoing research,therapeutic application	3,4,4,4	
2.7.11.20	Triple Negative Breast Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32793689&form=6&db=m	Cunning maneuver regulating chemotherapy resistance in triple-negative breast cancer by eEF2K and autophagy.	therapeutic application,unassigned	3,0	
2.7.11.20	Triple Negative Breast Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33911160&form=6&db=m	Inhibition of eEF2K synergizes with glutaminase inhibitors or 4EBP1 depletion to suppress growth of triple-negative breast cancer cells.	causal interaction,therapeutic application,unassigned	3,4,0	
2.7.11.20	Vesicular Stomatitis	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15542627&form=6&db=m	Resistance to vesicular stomatitis virus infection requires a functional cross talk between the eukaryotic translation initiation factor 2alpha kinases PERK and PKR.	causal interaction,ongoing research,therapeutic application,unassigned	2,1,3,0	
2.7.11.20	Virus Diseases	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11756670&form=6&db=m	Regulation of starvation- and virus-induced autophagy by the eIF2alpha kinase signaling pathway.	therapeutic application,unassigned	1,0	
2.7.11.20	Virus Diseases	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16373505&form=6&db=m	Tyrosine phosphorylation acts as a molecular switch to full-scale activation of the eIF2alpha} RNA-dependent protein kinase.	unassigned	-	
2.7.11.20	Virus Diseases	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19436736&form=6&db=m	P58: A Novel "CIHD" Member of the Host Innate Defense Response against Pathogenic Virus Infection.	therapeutic application,unassigned	2,0	
2.7.11.20	Virus Diseases	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19461876&form=6&db=m	P58(IPK): a novel "CIHD" member of the host innate defense response against pathogenic virus infection.	therapeutic application,unassigned	2,0	
2.7.11.20	Virus Diseases	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22114338&form=6&db=m	Increased susceptibility to DNA virus infection in mice with a GCN2 mutation.	causal interaction,therapeutic application,unassigned	2,1,0	
2.7.11.20	Virus Diseases	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23110064&form=6&db=m	GCN2 has inhibitory effect on human immunodeficiency virus-1 protein synthesis and is cleaved upon viral infection.	causal interaction,therapeutic application,unassigned	4,1,0